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ABSTRACT
Objective To determine whether screening and treating
women for chlamydial infection reduces the incidence of
pelvic inflammatory disease over the subsequent
12 months.
Design Randomised controlled trial.
Setting Common rooms, lecture theatres, and student
bars at universities and further education colleges in
London.
Participants 2529 sexually active female students, mean
age 21 years (range 16-27).
Intervention Participants completed a questionnaire and
provided self taken vaginal swabs, with follow-up after
oneyear.Sampleswererandomlyallocatedtoimmediate
testing and treatment for chlamydial infection, or storage
and analysis after a year (deferred screening controls).
Main outcome measure Incidence of clinical pelvic
inflammatory disease over 12 months.
Results Baseline prevalence of chlamydia was 5.4%
(68/1254) in screened women and 5.9% (75/1265) in
controls. 94% (2377/2529) of women were followed up
after 12 months. The incidence of pelvic inflammatory
disease was 1.3% (15/1191) in screened women
compared with 1.9% (23/1186) in controls (relative risk
0.65, 95% confidence interval 0.34 to 1.22). Seven of 74
control women (9.5%, 95% confidence interval 4.7% to
18.3%) who tested positive for chlamydial infection at
baseline developed pelvic inflammatory disease over
12 months compared with one of 63 (1.6%) screened
women (relative risk 0.17, 0.03 to 1.01). However, most
episodes of pelvic inflammatory disease occurred in
women who tested negative for chlamydia at baseline
(79%,30/38).22%(527/2377)ofwomenreportedbeing
tested independently for chlamydia during the trial.
Conclusion Although some evidence suggests that
screening for chlamydia reduces rates of pelvic
inflammatory disease, especially in women with
chlamydial infection at baseline, the effectiveness of a
single chlamydia test in preventing pelvic inflammatory
disease over 12 months may have been overestimated.
Trial registration ClinicalTrials.gov NCT00115388.
INTRODUCTION
GenitalinfectionwithChlamydiatrachomatisisthemost
commonbacterialsexuallytransmittedinfectioninthe
UnitedStatesandEurope,withoverthreemillionnew
infectionsdiagnosedeachyear.
12But mostchlamydial
infections remain asymptomatic and undiagnosed.
3
Untreated chlamydial infection in women can lead to
pelvic inflammatory disease, causing scarring of the
fallopian tubes, which can result in tubal infertility,
chronic pelvic pain, and ectopic pregnancy. The
annual cost of chlamydial infection and its sequelae in
the United States has been estimated to exceed $2bn.
2
In many developed countries, screening pro-
grammes for chlamydia have been set up to reduce
transmission and reproductive tract morbidity.
2 The
US Centers for Disease Control and Prevention
recommend annual screening of all sexually active
women aged 25 or less.
1 In England the recommenda-
tionappliestowomenaged24orless.
2Butcontroversy
remains about the evidence base. The results of the
landmark trial by Scholes et al
4 have been
questioned,
5-7andthecontinuingsearchforsupporting
evidence from other randomised controlled trials and
epidemiologicalstudieshasnotbeenalwaysfruitful.
8-11
The UK National Institute for Health and Clinical
Excellence recommended improvements in the qual-
ity of randomisation, allocation concealment, and
blinding of assessment of outcome in any future trials
of chlamydia screening.
3 A more accurate estimate of
the rate of progression of genital chlamydial infection
to pelvic inflammatory disease is also urgently needed
to evaluate the cost effectiveness of screening
programmes.
12 However, neither of the two previous
trials
49 tested all the control women. No trials of
chlamydia screening have taken place in a British
population.
The national chlamydia screening programme was
progressively rolled out across England from 2003 to
2008. This left a window of opportunity from 2004 to
2007 to carry out a community based trial in a non-
healthcare setting using self taken samples. In the
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gated whether screening young sexually active female
students for chlamydial infection and treating those
found to be infected reduced the incidence of pelvic
inflammatory disease in the subsequent 12 months.
Wealsocarriedoutanexploratorystudytoinvestigate
theincidenceofpelvicinflammatorydiseaseinwomen
with untreated chlamydial infection.
13
METHODS
The design and recruitment methods have been pub-
lished elsewhere.
13-15 Briefly, women were eligible for
inclusioniftheywereaged27orlessandweresexually
active.Weexcludedwomenwhohadneverhadsexual
intercourse,hadbeentestedforchlamydialinfectionin
the past three months, or were pregnant. Female
nurses, research assistants, the principal investigator
(PO), and peers recruited women in bars, common
rooms, and lecture theatres at 20 London universities
andfurthereducationcolleges.(Furthereducationcol-
leges take students from age 16 and teach both aca-
demic subjects and vocational subjects, such as
hairdressing.)
Participants provided written informed consent.
13
They were warned of the risks of chlamydial infection
and that their samples might not be tested for a year
and were advised to get checked independently if
they thought they had been at risk.
Procedures
Participants were asked to complete a brief confiden-
tial questionnaire on sexual health; to provide self
taken vaginal samples in the nearest lavatory; and to
allow access to their medical records, with follow-up
afterayear.
13Withintwoweeksofrecruitmentweran-
domlyallocatedsealedsamplepacks,whichcontained
the completed, unopened questionnaires and consent
forms, into two groups using random number tables.
Vaginalswabsfrompacksallocatedtotheintervention
group were tested for C trachomatis using transcription
mediatedamplification(TMA;Gen-Probe,SanDiego,
CA). Vaginal swabs from packs allocated to deferred
screening were stored at −80°C and analysed one year
later. PO contacted infected women within two weeks
of diagnosis and asked them to attend their local geni-
tourinary medicine clinic or general practitioner for
treatment and partner notification. Vaginal smears
made at baseline were Gram stained and examined
for bacterial vaginosis using Nugent’s criteria.
1617
Ayearafterrecruitment,weaskedtheparticipantsto
complete a secure online questionnaire about possible
symptomsofpelvicinflammatorydisease(pelvicpain,
dyspareunia, bleeding between menstrual periods, or
abnormal vaginal discharge) and sexual behaviour
during the past year. Those who did not respond or
provide an email address were sent the questionnaire
by post, backed up by telephone reminders. We fol-
lowed up non-responders through their general prac-
tice records. For all women (or their general
practitioner) who reported that during the past
12monthstheyhadhadtreatmentforpelvicinflamma-
tory disease, had a laparoscopy, seen a health profes-
sional for abdominal or pelvic pain, been treated for a
urinary tract infection, or reported three of four possi-
ble symptoms of pelvic inflammatory disease, we
endeavoured to obtain copies of the clinical findings
from medical records of general practitioners, hospi-
tals, family planning clinics, and genitourinary medi-
cine clinics. After anonymisation of data, three
genitourinary doctors blinded to group allocation and
baseline chlamydia status used modified Hager’s
criteria
18 and Centers for Disease Control guidelines
1
to classify cases into probable, possible, or not pelvic
inflammatory disease.
13 Cases were categorised inde-
pendently by two doctors, with review by a third for
disagreements.
Masking
Participants were blind to group allocation except for
those in the intervention group with baseline samples
that tested positive for chlamydia and who were
referred for treatment, and 38 women with indetermi-
nate test results who were asked to post a repeat sam-
ple. Investigators were blind during recruitment and
follow-up except PO when she referred women with
chlamydial infection for treatment. Categorisation of
pelvic inflammatory disease status was also blind.
13
Statistical analysis
Assuming a 2% incidence of pelvic inflammatory dis-
ease in the control group, we needed a sample of 4122
womentodetectarelativeriskof0.48with80%power
and 5% significance. We had difficulty with
recruitment,
1415 however, as we were asking women
who were not attending college for health reasons to
provide vaginal samples that might not be tested for a
year. Two studies
919suggested a higher rate of pelvic
inflammatory disease, enabling us to revise down our
sample size calculations. Assuming a 3% incidence of
pelvicinflammatorydiseaseinthecontrolgroup,
919we
Deferred screening control group (n=1270)
(samples frozen at -80 °C for 12 months)
Screened group (n=1259)
Chlamydia positive (n=68)
Referred for treatment and partner notification
  (n=65)
Women enrolled and provided vaginal samples; sealed sample packs also containing consent
forms and baseline questionnaires were randomly allocated into two groups (n=2563)
Followed up by questionnaire or general practice
  record search after 12 months (n=1191, 95%)
Selected for additional medical record search
  (n=218)
Reported being tested independently for
  chlamydia (n=269)
Followed up by questionnaire or general practice
  record search after 12 months (n=1186, 93%)
Selected for additional medical record search
  (n=178)
Reported being tested independently for
  chlamydia (n=258)
Excluded (n=20):
  Age >27 years (n=6)
  Never been sexually active (n=7)
  No swab provided (n=4)
  Enrolled twice (n=3)
Excluded (n=14):
  Age >27 years (n=6)
  Never been sexually active (n=3)
  No swab provided (n=3)
  Enrolled twice (n=2)
Lost to follow-up (3 withdrew) (n=68) Lost to follow-up (5 withdrew) (n=84)
Trial profile
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risk of 0.44
413 with 80% power and 5% significance.
Recruiting 2500 women allowed for 10% loss to fol-
low-up.
For the primary analysis we estimated the relative
risk of developing pelvic inflammatory disease in the
12 months after recruitment to the screened group
compared with the deferred screening control group.
In secondary analyses we examined the proportion of
control women with untreated chlamydial infection
who developed pelvic inflammatory disease within
12 months. We used exact methods to compute confi-
dence intervals for unadjusted relative risks.
20 To
adjust the relative risk of pelvic inflammatory disease
for symptoms at baseline we also carried out an
exploratory binomial regression using Stata version
10. Thirty five samples randomly allocated to the
screeninggroupwereunintentionallyputinthefreezer
and not tested for C trachomatis for 12 months. All par-
ticipants were, however, analysed according to their
original group allocation.
RESULTS
Between September2004 and October 2006, 2563 eli-
gible women were recruited and randomised (figure).
We were unable to obtain information on all non-par-
ticipants,butrecruitmentformscompletedearlyinthe
study suggested 41% of 956 ineligible women had
never had sexual intercourse, 24% were outside the
age range, and 13% had been tested for chlamydial
infectioninthepreviousthreemonths.
13Asurveydur-
ing three recruitment sessions suggested that eligible
women refusing to participate were more likely than
responders to be from ethnic minority groups.
15 After
34 exclusions (figure), 2529 women (mean age
20.9 years) were included in the study. Baseline char-
acteristics of participants were similar between the
screened and deferred screening groups except that
more women in the screened group reported symp-
toms in the six months before recruitment (table 1).
Chlamydial infection and treatment at baseline
Sixty eight (5.4%) women in the screened group tested
positive for chlamydia at baseline. PO contacted 65 of
the women to ask them to attend their local genitour-
inary medicine clinic or general practitioner for treat-
ment and partner notification. Two women could not
be contacted directly as their mobile telephone num-
ber was not working, they did not provide an email
address, and they had requested no post to the home
address. The college nurses contacted them for us. A
further chlamydia positive sample from the 35 inter-
vention samples unintentionally put in the freezer
was not tested for 12 months. When telephoned after
1-2 months, 59 women confirmed they had been trea-
ted: 36 at a genitourinary medicine clinic, 12 by their
general practitioner, and three at a community sexual
health clinic. Eight women did not provide details.
When control samples were tested 12 months after
recruitment, 75 (5.9%) were positive for chlamydia.
Table 1 |Baseline characteristics of 2529 women allocated to immediate or deferred
screening for Chlamydia trachomatis. Values are percentages (numbers) unless stated
otherwise
Characteristics
Screened women
(n=1259)
Deferred screening controls
(n=1270)
Age (years):
<20 44.2 (557) 44.6 (567)
20-24 46.5 (585) 43.3 (550)
≥25 9.3 (117) 12.0 (153)
Ethnicity: n=1250 n=1262
White 63.0 (787) 60.1 (758)
Black Caribbean 8.5 (106) 9.5 (120)
Black African 15.3 (191) 17.4 (220)
Black other 2.3 (29) 1.7 (22)
South Asian 3.0 (35) 2.8 (35)
Chinese 1.0 (11) 0.7 (9)
Other 7.3 (91) 7.8 (98)
Recruited at university* 69.5 (875) 66.7 (847)
Cigarettes smoked per day: n=1253 n=1265
None 66.9 (838) 69.9 (884)
1-10 26.6 (333) 24.0 (304)
>10 6.5 (82) 6.1 (77)
Mean (SD) age at sexual debut 16.4 (1.8); n=1233 16.5 (1.8); n=1247
No of sexual partners in past year: n=1251 n=1262
None 3.4 (42) 4.2 (53)
1 52.0 (650) 54.6 (689)
2 23.1 (289) 21.2 (268)
>2 21.6 (270) 20.0 (252)
Contraception: n=1243 n=1260
None 7.6 (95) 8.0 (101)
Condoms 53.4 (664) 55.2 (695)
Contraceptive pill 49.1 (610) 46.4 (585)
Implant, injection, or patch 5.1 (63) 5.3 (67)
Coil 1.7 (21) 1.7 (22)
Douching 0.2 (2) 0 (2)
Symptoms in past 6 months: n=1242 n=1254
Pelvic pain 13.7 (170) 11.8 (148)
Dyspareunia 13.1 (163) 10.0 (125)
Bleeding between menstrual
periods
14.1 (175) 11.3 (142)
Abnormal vaginal discharge 12.6 (157) 10.7 (134)
Any symptoms 36.6 (455) 31.3 (393)
Reported history of sexually
transmitted infection ever:
n=1190 n=1219
Chlamydia 5.9 (70) 6.6 (80)
Genital warts 1.2 (14) 1.2 (15)
Genital herpes 0.6 (7) 0.9 (11)
Bacterial vaginosis 0.9 (11) 0.5 (6)
Gonorrhoea 0.3 (4) 0.2 (2)
Reported history of pelvic
inflammatory disease:
n=1252 n=1265
2.1 (26) 0.9 (12)
Baseline infections:
Chlamydia† 5.4 (68); n=1254 5.9 (75); n=1265
Bacterial vaginosis 20 (241); n=1191 21 (248); n=1193
*Not further education colleges.
†No results were available for 10 baseline samples (five intervention, five control). Three intervention samples
were indeterminate or inhibitory and participants failed to return a repeat baseline postal sample, four samples
leaked, and three control samples were either lost or the labels were illegible after defrosting.
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Overall,94%(2377/2529)ofthewomenwerefollowed
upafter 12 months.Nearly half(47%, 1108) repliedby
email, 32% (n=760) by postal questionnaire, 8%
(n=199)by telephone, and13% (n=310)were followed
up by questionnaire to their general practitioner. The
152 women lost to follow-up were younger (mean age
20.0 years (SD 2.5) v 21.0 (SD 2.8); P<0.01) and more
likely to be of black ethnicity (46% (68/149) v 26%
(620/2363); P<0.01) than the remainder. Table 2
gives details of the 396 women who were selected, on
the basis of questionnaire responses, for more detailed
assessment and search of medical records.
Incidence of pelvic inflammatory disease
Theincidenceofpelvicinflammatorydiseasewas1.3%
(15/1191) in screened women compared with 1.9%
(23/1186) in controls (relative risk 0.65, 95% confi-
dence interval 0.34 to 1.22, table 3). After adjustment
for symptoms at baseline the relative risk was 0.57
(0.29 to 1.11). The overall incidence of pelvic inflam-
matory disease over 12 months was 1.6% (38/2377,
95% confidence interval 1.1% to 2.1%).
Ratesofpelvicinflammatorydiseasewereexamined
inthe137womenwithchlamydialinfectionatbaseline
who were followed up for 12 months. Seven of 74
women in the deferred screening group developed
clinical pelvic inflammatory disease (incidence 9.5%,
4.7% to 18.3%). All seven women were tested for C
trachomatis at the time pelvic inflammatory disease
wasdiagnosedandfivetestedpositive.Bycomparison,
only one of 63 (1.6%) screened and treated women
positive for chlamydia developed clinical pelvic
inflammatory disease (relative risk 0.17, 0.03 to 1.01).
Initial treatment for chlamydial infection in this
womanwasconfirmedbytelephonebutshedeveloped
symptoms of pelvic inflammatory disease and tested
positive for chlamydia 26 weeks after recruitment.
Onthe12monthquestionnaireshereportedthreesex-
ual partners in the previous year and no use of con-
doms.
Most cases of pelvic inflammatory disease (79%,
30/38) occurred in women who tested negative for
chlamydia at baseline. Chlamydia test results at the
time pelvic inflammatory disease was diagnosed were
availablefor26(of38)women,ofwhom16testedposi-
tive for chlamydial infection. Ten of these 16 women
were negative for chlamydia at baseline. Seventy per
cent (21/30) of women with pelvic inflammatory dis-
ease who completed the 12 months’ questionnaire
reported having had two or more sexual partners dur-
ingtheyear.Thegroupsshowedaslightimbalancefor
reported symptoms but similar sexual behaviour dur-
ing the follow-up period (table 4).
Independent testing during follow-up
Overall, 527 (22%) participants reported having been
tested independently for chlamydia (figure); 15%
(n=38) of the control women and 10% (n=27) of the
screened women said they tested positive. Those
women in the deferred screening group (blind to
group allocation and baseline chlamydia status) who
Table 2 |Details of follow-up for potential pelvic inflammatory disease (PID) over 12 months. Values are numbers unless
stated otherwise
Variables
Screened women
(n=1259)
Deferred screening
controls (n=1270)
% (No) followed up by questionnaire to participant or general practitioner 94.6 (1191) 93.4 (1186)
% (No) selected for additional record search for clinical details of potential PID: 17.3 (218) 14.0 (178)
Participant or general practitioner reported PID* 12 9
Laparoscopy 16 24
Visited doctor for abdominal or pelvic pain 108 95
Treated for urinary tract infection 50 22
Reported 3 of 4 symptoms† but did not report seeing doctor 32 28
*Some participants were in more than one category, but each is included only once, in hierarchical order.
†Pelvic pain, dyspareunia, bleeding between menstrual periods, or abnormal vaginal discharge.
Table 3 |Incidence of pelvic inflammatory disease (PID) in 2377 women followed up for 12 months. Values are percentages
(numbers) unless stated otherwise
Variables
Screened
women
Deferred screening
controls
Relative risk
(95% CI) P value
All PID: probable* and possible† 1.3 (15/1191) 1.9 (23/1186) 0.65 (0.34 to 1.22) 0.19
Probable PID 0.8 (10/1191) 1.3 (16/1186) 0.62 (0.29 to 1.34) 0.24
Rate of PID in women who were
positive for chlamydia at baseline
1.6 (1/63) 9.5 (7/74) 0.17 (0.03 to 1.01) 0.07
*Doctor assessed as probable—that is, clinical diagnosis of PID and treated
1; modified Hager’s criteria—pelvic pain, cervical motion tenderness,
uterine or adnexal tenderness.
18
†Abdominal pelvic pain with features of PID, which may have responded to antimicrobial therapy, but no record of cervical excitation or uterine or
adnexal tenderness; or long standing abdominal pain consistent with endometriosis, but some features of PID—for example, uterine tenderness, and
unable to confirm if antimicrobial therapy had a benefit.
1
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likely than those who were negative to report having
been tested independently (43%, 29/67 v 24%,
229/968; P<0.001).
DISCUSSION
The risk of clinical pelvic inflammatory disease over
12 months in women screened for C trachomatis was
non-significantly reduced by 35%. The overall inci-
dence of pelvic inflammatory disease was, however,
low (1.6%). In 137 women with chlamydial infection
at baseline, 9.5% in the deferred screening control
group developed pelvic inflammatory disease com-
pared with only 1.6% in the screened group. Over
90% (67/74) of control women with chlamydial infec-
tion at baseline did not develop clinical pelvic inflam-
matory disease; and most cases (79%, 30/38) of pelvic
inflammatorydisease,including10casesofchlamydia
positive pelvic inflammatory disease, occurred in
women who were negative for chlamydia at baseline,
suggesting these were incident infections.
Strengths and limitations of the study
This is the first trial of chlamydia screening to obtain
samplesfordelayedchlamydiatestingfromthecontrol
women. Analysis of these samples enabled us to pro-
vide novel data on the risk of pelvic inflammatory dis-
ease in untreated women positive for chlamydia in the
community,whichcan nowbeusedformodellingand
cost effectiveness studies.
12 Secondly, this is the first
UK study to provide prospective data on the overall
risk of clinical pelvic inflammatory disease in a large
cohortofsexuallyactiveyoungwomeninthe commu-
nity.Thirdly,thisisthemostrobusttrialtodate.
38Ran-
domisation was done blind and after recruitment
6 and
themainoutcomewasassessedblind.The94%follow-
up was a major achievement in this young, mobile,
mainly inner city population, requiring repeated tele-
phonecallsandemails.Wealsoobtaineddataoninde-
pendent chlamydia testing and treatment in both
groups. Participants came from a wide range of back-
grounds and included 1124 sexually active teenagers
of whom 46% came from ethnic minorities. As in the
English national chlamydia screening programme, we
used self taken samples and routine management of
infected women. Vaginal swabs are more sensitive
than urine samples for the detection of chlamydia.
21
The main weakness is that despite a similar sample
size (2529 v 2607) and incidence of pelvic inflamma-
tory disease (1.6% v 1.7%) to the Scholes trial, screen-
ing twice as many women (1259 v 645) and treating
more women with chlamydial infection (67 v 44), the
trial was underpowered. The annual incidence of pel-
vicinflammatorydiseasewaslessthanthe3%
91319used
in the sample size calculations, and screening did not
reduce the risk by at least 50%.
4 Secondly,participants
were advised to be screened independently, and the
one in five who acted on this advice had a high preva-
lence of chlamydial infection. The rate of independent
testing reported by women in the deferred screening
group who were positive for chlamydia at baseline
was even higher (43%). It is likely that this reduced
theeffectoftheintervention.Thirdly,theclinicaldiag-
nosis of pelvic inflammatory disease lacks sensitivity
22
and specificity, which is also likely to attenuate the
effect size.
8 The diagnosis of pelvic inflammatory dis-
ease depended on the women seeing a health
professional,
7 and the women’s reports of possible
symptoms or consultations for pelvic inflammatory
disease may be unreliable, particularly for those who
could be followed up only by telephone questionnaire
(10% of controls, 7% of screened women), and who
might tend to respond negatively to questions. We
were able to obtain detailed medical records only of
the 17% of women with potential pelvic inflammatory
disease. In addition, the medical records were some-
times incomplete and many women changed address
and general practitioner during the study period or
attended different hospitals and clinics. Finally, as
withallrandomisedclinicaltrials,thestudyhaslimited
generalisabilityandmaynotapplytodifferentpopula-
tions such as women attending healthcare facilities,
those from different ethnic groups, higher risk
women such as sex workers, or non-UK populations.
Comparison with other studies
Only two trials have been carried out on chlamydia
screening to prevent pelvic inflammatory disease in
non-pregnantwomen.
8TheseweredoneintheUnited
States and Denmark and started in 1990 and 1997.
49
The trial by Scholes et al involved 2607 women from
a health maintenance organisation.
8 However, over a
third of the women (n=364) in the intervention group
were not screened, and these women had a low rate of
pelvic inflammatory disease (0.5%, 2/364) leading to a
relative risk of pelvic inflammatory disease in those
allocated to screening compared with usual care of
0.44 (95% confidence interval 0.20 to 0.90). Pelvic
inflammatory disease is polymicrobial, but in many
casesnopathogensareisolated.Ifchlamydialinfection
is implicated in only about 30% of cases of pelvic
inflammatory disease, even if screening and treatment
prevented all cases of pelvic inflammatory disease due
to chlamydia, it would be unlikely to halve the overall
risk of pelvic inflammatory disease.
8 Recently, the
Table 4 |Reported symptoms of potential pelvic inflammatory disease and sexual behaviour
over 12 months in 2057 women who completed follow-up questionnaires
Reported symptoms and
behaviour
% (No) of women
Screened women
(n=1029)
Deferred screening controls
(n=1028)
Pelvic pain 11.0 (113) 10.2 (105)
Dyspareunia 10.9 (112) 9.3 (96)
Bleedingbetweenmenstrualperiods 13.5 (139) 12.8 (132)
Abnormal vaginal discharge 15.2 (156) 13.0 (134)
Any symptom 34.0 (350) 31.3 (322)
≥2sexualpartnersinpast12months 36.7 (367); n=1001 37.6 (377); n=1003
Condom use 54.5 (538); n=987 56.5 (557); n=985
Sexually transmitted infection in
past 12 months
4.8 (48); n=1007 5.2 (52); n=1000
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In a later trial in 1700 female high school students,
Ostergaard et al found that 2.1% of those in the home
sampling group and 4.2% in the usual care group
reported treatment for pelvic inflammatory disease
when interviewed after a year.
9 Ascertainment of pel-
vicinflammatorydiseasewas,however,unblindedand
nearly 50% of the women were lost to follow-up.
8 In
addition, reports by the women might be unreliable,
as masked analysis of clinical data in our trial con-
firmed pelvic inflammatory disease in only 11 of the
21 women whose questionnaires reported that they
had had pelvic inflammatory disease. Finally, the inci-
dence of pelvic inflammatory disease in our trial was
slightly lower than the 2.3% found in similar aged
women attending English and Welsh general
practices.
23 The women in our study with pelvic
inflammatory disease were assessed by doctors in gen-
itourinary medicine, and both coding and diagnosis
may be more reliable. It is, however, likely that the
incidence of pelvic inflammatory disease would be
higher in those lost to follow-up, sexually active teen-
agers aged <16, or those not in education.
Implications
This is the only chlamydia screening trial with this
design ever likely to be done in a developed country.
This is because of ethical issues with delayed chlamy-
diatestingandthewidespreadintroductionofchlamy-
dia screening programmes. Although some evidence
showsthatscreeningreducedratesofpelvicinflamma-
tory disease, especially in women with chlamydial
infectionatbaseline,the absolutenumberofcasespre-
vented was small. Our findings suggest that to prevent
one case of clinical pelvic inflammatory disease over
12 months, it may be necessary to screen 147 women
for chlamydial infection or to treat 13 women who are
positive for chlamydia. These numbers are greater
than previously suggested.
811If the incidence of pelvic
inflammatorydiseaseinwomenwithchlamydialinfec-
tionhasbeenoverestimated,andparticularlyifitisless
than 10%,
24 then the cost effectiveness of screening
might be exaggerated.
810
Most cases of pelvic inflammatory disease over
12 months were not prevented by a single chlamydia
screen and occurred in women who were negative for
chlamydia at baseline.This suggests the importance of
incidentinfection.Policymakersmightconsiderfocus-
ing on more frequent testing of those at higher risk,
such as women with a new sexual partner or a recent
history of chlamydial infection.
112526
We thank the students and staff at London Southbank University;
Kingston University; City University; St George’s, University of London;
Roehampton University; London College of Fashion; London College of
Communication; University of East London; Greenwich University;
University of Westminster; Wimbledon School of Art; Kingston College;
Lambeth College; Southwark College; South Thames College; Lewisham
College; Bromley College; North East Surrey College of Technology;
Carshalton College; Merton College; Coulsdon College; and Croydon
College. We also thank research assistants Deborah Banks, Ruth Harbit,
and Stella Ivaz; research nurses Sally Dean and Cathy McKay; peer
recruiters Linzie Long, Michelle Lamb, Laura Proctor, Sarah Simms, Sarah
Kerry,andSheilaKerry,andgrantadministratorFrancesKazakos.Wealso
thank Drs Harry Mallinson and Jorgen Jensen for doing the chlamydia
tests;DrsElizabethWilliams,KatiaPrime,andPaddyHornerforanalysing
the data on pelvic inflammatory disease; and the staff at the general
practices, genitourinary medicine clinics, sexual health clinics, and
hospitals who provided copies of medical records.
Contributors. PEH, PO, and SK conceived and designed the study. All
authorshelped draft and revise the article and approved the finalversion
to be published. PO and SK are guarantors.
Funding: This study was supported by the BUPA Foundation (grant No
684/GB14B). TMA sample collecting kits were provided by Gen-Probe
(San Diego, CA).
Competing interests: All authors have completed the unified competing
interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare (1) no financial support for
the submitted work from anyone other than their employer; (2) no
financial relationships with commercial entities that might have an
interest in the submitted work; (3) no spouses, partners, or children with
relationships with commercial entities that might have an interest in the
submittedwork;and(4)nonon-financialintereststhatmayberelevantto
the submitted work.
Ethical approval: This study was approved by Wandsworth research
ethics committee (reference 03.0012).
Data sharing: No additional data available.
1 CentersforDiseaseControl.Sexuallytransmitteddiseasestreatment
guidelines. MMWR 2006;55:56-7.
2 European Centre for Disease Prevention and Control. Chlamydia
control in Europe. ECDC, 2009.
3 National Institute for Health and Clinical Excellence. Revised rapid
review of evidence for the effectiveness of screening for genital
chlamydia infection in sexually active young women and men. NICE,
2006.
4 Scholes D, Stergachis A, Heidrich F, Andrilla H, Holmes K, Stamm W.
Prevention of pelvic inflammatory disease by screening for cervical
chlamydia infection. NE n g lJM e d1996;334:1362-6.
5 Abter E, Mahmud M. Screening for chlamydia to prevent pelvic
inflammatory disease. NE n g lJM e d1996;335:1531.
6 Sellors J, Paavonen J. Screening to prevent pelvic inflammatory
disease. NE n g lJM e d1996;335:1531-2.
7 Pittrof R. Screening for chlamydia to prevent pelvic inflammatory
disease. NE n g lJM e d1996;335:1532.
8 Low N, Bender N, Nartey L, Shang A, Stephenson J. Effectiveness of
chlamydia screening: systematic review. Int J Epidemiol
2009;38:435-48.
9 Ostergaard L, Andersen B, Moller JK. Home sampling versus
conventional swab samplingfor screening of Chlamydia trachomatis
in women: a cluster randomised 1-year follow-up study. Clin Infect
Dis 2000;31:951-7.
10 Low N, Egger M, Sterne JAC, Harbord R, Ibrahim F, Lindblom B, et al.
Incidenceofseverereproductivetract complicationsassociatedwith
WHAT IS ALREADY KNOWN ON THIS TOPIC
Chlamydiatrachomatiscancausepelvicinflammatorydisease(PID)leadingtotubalinfertility
and ectopic pregnancy
Annualtestingofallsexuallyactivewomenaged24orlessiswidelyrecommendedandmany
developed countries have set up chlamydia screening programmes
The evidence base has been questioned
WHAT THIS STUDY ADDS
While screening and treatment of chlamydial infection might reduce the risk of clinical PID
over12months,especiallyinwomenwithchlamydialinfectionatbaseline,mostcasesofPID
occurred in women who tested negative for chlamydia at baseline, suggesting incident
infection
The effectiveness of a single chlamydia test in preventing PID over 12 months might have
been overestimated
Policymakersmightconsiderfocusingonmorefrequenttestingofwomenathigherrisk,such
as those with a recent change of sexual partner or history of chlamydial infection in the past
three months
RESEARCH
page 6 of 7 BMJ | ONLINE FIRST | bmj.comdiagnosed genital chlamydial infection: the Uppsala Women’s
Cohort study. Sex Transm Infect 2006;82:212-8.
11 Peterman T, Gottlieb S, Berman S. Commentary: Chlamydia
trachomatis screening—what are we trying to do? Int J Epidemiol
2009;38:449-51.
12 SimmsI,HornerPJ.Hastheincidenceofpelvic inflammatorydisease
following chlamydia infection been overestimated? Int J STD AIDS
2008;18:285.
13 Oakeshott P, Kerry S, Atherton H, Aghaizu A, Hay S,
Taylor-Robinson D, et al. Community-based trial of screening for
Chlamydia trachomatis to prevent pelvic inflammatory disease: the
POPI (Prevention of Pelvic Infection) trial. Trials 2008;9:73.
14 Ivaz S, Dean S, Hay P, Hay S, Kerry S, Oakeshott P. Lessons learned
from recruiting young female students to a randomised controlled
trial of chlamydia screening. Fam Pract 2006;23:188-91.
15 Atherton H, Banks D, Hay P, Kerry S, Simms I, Oakeshott P.
Recruitment of young women to a trial of chlamydia screening—as
easy as it sounds? Trials 2007;8:41.
16 Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial
vaginosis is improved by a standardized method of Gram stain
interpretation 36. J Clin Microbiol 1991;29:297-301.
17 Oakeshott P, Hay P, Hay S, Steinke F, Rink E, Kerry S. Association
between bacterial vaginosis or chlamydial infection and miscarriage
before 16 weeks’ gestation: prospective community based cohort
study. BMJ 2002;325:1334-6.
18 Hager D, Eschenbach D. Criteria for diagnosis and grading of
salpingitis. Obstet Gynecol 1983;61:113-4.
19 Ness RB, Hillier SL, Kip K, Soper D, Stamm CA, McGregor JA, et al.
Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet
Gynecol 2004;104:761-9.
20 Miettinen OS, Nurminen M. Comparative analysis of two rates. Stat
Med 1985;4:213-26.
21 Schachter J, Chernesky MA, Willis DE, Fine PM, Martin DH, Fuller D,
et al. Vaginal swabs are the specimens of choice when screening for
Chlamydia trachomatis and Neisseria gonorrhoeae: results from a
multicenter evaluation of the APTIMA assays for both infections 1.
Sex Transm Dis 2005;32:725-8.
22 Ness R, Soper D, Holley RL, Peipert J, Randall MD, Sweet R, et al.
Effectiveness of inpatient and outpatient treatment strategies for
women with pelvic inflammatory disease: results from the Pelvic
Inflammatory Disease Evaluation and Clinical Health (PEACH)
randomised trial. Am J Obstet Gynecol 2002;186:929-37.
23 SimmsI, Rogers P, Charlett A. The rateof diagnosis and demography
of pelvic inflammatory disease in general practice: England and
Wales. Int J STD AIDS 1999;10:448-51.
24 Adams EJ, Turner K, Edmunds WJ. The cost effectiveness of
opportunistic chlamydia screening in England. Sex Transm Inf
2007;83:267-75.
25 Low N, Ward H. Focus on chlamydia. Sex Transm Inf 2007;83:251-2.
2 6 G a y d o sC A ,W r i g h tC ,W o o dB J ,W a t e r f i e l dG ,H o b s o nS ,Q u i n nT C .
Chlamydia trachomatis reinfection rates among female adolescents
seeking rescreening in school-based health centers. Sex Transm Dis
2008;35:233-7.
Accepted: 16 February 2010
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 7